OTC · CERO
Healthcare · Biotechnology
$0.00
Up+$0.00 (+0.00%)
Updated Nov 3, 2026, 2:43 PM
SID Score
3.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · CERO
1M range · 0 trading sessions · Daily adjusted prices
CERO does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning CERO.
Company
Market Activity
Research & News
CERO research
Company profile and research snapshot.
CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies and solid tumors. The company was incorporated in 2021 and is based in South San Francisco, California.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Nov 18, 2025 | D. Boral Capital | Hold | — |
| Nov 3, 2025 | Maxim Group | Hold | — |
| Oct 30, 2025 | D. Boral Capital | Buy | — |
| Oct 22, 2025 | D. Boral Capital | Buy | — |
| Oct 13, 2025 | D. Boral Capital | Buy | — |
No generated briefing is available yet.
Benzinga · Oct 26, 2026
UC Davis is the primary manufacturing site for CER-1236, site activation is expected to expand patient recruitment capacity and streamline treatment logisticsUpdate follows SRX’s previously announced definitive
globenewswire.com · Dec 2, 2025
Company's Shares Will Continue to Trade Under Ticker CERO SOUTH SAN FRANCISCO, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (OTCQB : CERO) (“CERo” or the “Company”), an innovative cellular immunotherapy company developing novel T cell therapeutics that incorporate phagocytic mechanisms, announces its shares will be available to trade on the OTCQB market under the ticker symbol CERO effective today, December 2, 2025 as of 8:00AM ET.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning CERO.
